Alnylam Pharmaceuticals, Inc.

Tekmira Pharmaceuticals Corporation

Narayanannair K Jayaprakash

Muthiah Manoharan

Kallanthottathil G Rajeev

Martin A Maier

Muthusamy Jayaraman

Akin Akinc

Shigeo Matsuda

Michael E Jung

David Butler

Pachamuthu Kandasamy

Thomas A Baillie

Rajendra K Pandey

Alexander V Kelin

Kallanthottahil G Rajeev

Jeremy Lackey

Muthusamy Jayraman

Chang Geng Peng

Takeshi Yamada

Rajeev G Kallanthottathil

This invention relates to an oligonucleotide comprising one or more abasic nucleoside monomers of formula V: These monomers are useful for modifying of oligonucleotides at one or more positions. This invention also relates to a method of inhibiting the expression of a target gene in a cell. The method comprises contacting the cell with an oligonucleotide having one or more of the above formula (V).

Oligonucleotides comprising acyclic and abasic nucleosides and analogs

The invention features compounds of formula (V) or (XII). In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. 

Monomers and oligonucleotides comprising cycloaddition adduct(s)

The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Biodegradable lipids for the delivery of active agents

The invention features compounds of formula I or II:  In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.

Chemical modifications of monomers and oligonucleotides with cycloaddition

The present invention provides iRNA agents comprising at least one subunit of the formula (I):  

Carbohydrate conjugates as delivery agents for oligonucleotides

Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Lipid containing formulations

Growing community of inventors

Cambridge, MA, United States of America

Narayanannair K Jayaprakash